RUNNING PROJECTS

PROJECTS SUPPORTED BY MINISTRY OF EDUCATION, YOUTH AND SPORTS OF THE CZE

OPERATIONAL PROGRAMME JOHANNES AMOS COMENIUS 

CZ.02.01.01/00/23_020/0008535 (UNIVERSITY HOSPITAL NUMBER - 9564)

ADVANCED TECHNIQUES FOR BIOMEDICAL DIAGNOSTICS (ATEBIO)

Chromed role: CO-INVESTIGATOR

Duration: 1st January 2025 - 31st December 2028

PROJECTS SUPPORTED BY MINISTRY OF HEALTH OF THE CZECH REPUBLIC

NW25-04-00246 (AZV ????)

THE ROLE OF KYNURENINES IN THE PATHOPHYSIOLOGY OF THE INFLAMMANTORY RESPONSE AND VASOSPASM IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE

NW25-01-00008 (AZV ????)

ANALYSIS OF ALTERED PLATELET AGGREAGTION PATHWAYS IN PATIENTS WITH DIABETES MELLITUS AND THE SEARCH FOR A NEW ANTIPLATELET DRUG IN THESE PATIENTS

Chromed role: TEAM MEMBER

Duration: 1st May 2025 - 31st December 2028

NW24-05-00031 (AZV 9037)

NON-INFECTIOUS MANIFESTATIONS AND DYSREGULATION OF THE IMMUNE SYSTEM IN PRIMARY ANTIBODY IMMUNODEFICIENCIES - A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS, RISK ASSESSMENT AND TREATMENT

Chromed role: CO-INVESTIGATOR

Duration: 1st May 2024 - 31st December 2027

NU22-01-00151 (AZV 9001)

PREDICTION OF CARDIOVASCULAR RISK AND PROGNOSIS IN PATIENTS WITH HYPERCHOLESTEROLAEMIA BY GENOMIC AND METABOLOMIC ANALYSIS

Chromed role: TEAM MEMBER

Duration: 1st May 2022 - 31st December 2025

PROJECTS SUPPORTED BY UNIVERSITY HOSPITAL HRADEC KRÁLOVÉ

IV 8145

DEVELOPMENT OF A NEW MINIATURIZED EXTRACTION TECHNIQUE USING VERY SMALL VOLUMES OF BIOLOGICAL MATERIAL FOR CLINICAL RESEARCH AND PRACTICE

Chromed role: MAIN INVESTIGATOR

Duration: 1st February 2025 - 31st December 2025

PROJECTS GIVEN BY GRANT AGENCY OF CHARLES UNIVERSITY

GAUK 121124

ADVANCED AND ALTERNATIVE APPROACHES TO VITAMIN K ANALYSIS IN CLINICAL PRACTICE USING DRY BLOOD SPOTS 

Chromed role: MAIN INVESTIGATOR

Duration: 1st January 2024 - 31st December 2026

COMPLETED PROJECTS

EUROPEAN PROJECTS

CZ.02.1.01/0.0/0.0/17_048/0007441 PERSONMED

The aim of the project is to establish and stabilize the system of acquiring and verifying promising multidisciplinary research results with high potential for the application of these scientific outputs to treatment and diagnostic procedures in the field of the personalized medicine. Then to examine a set of promising results in terms of their applicability and to ensure their protection. Last but not least, to take advantage of the quality of the research topics developed at the participating institutions in the international competition and to build expert consortia.

Chromed role: COOPERATOR

Duration: 1st January 2018 - 31st December 2022 (extended to 30th June 2023)

PROJECTS SUPPORTED BY UNIVERSITY HOSPITAL HRADEC KRÁLOVÉ

IV 8145

TESTING NEW NANOFIBROUS MATERIALS FOR APPLICATION IN MICROSAMPLING TECHNIQUES

Chromed role: MAIN INVESTIGATOR

Duration: 1st February 2024 - 31st December 2024

IV 8145 

MICROSAMPLING AND MICROEXTRACTION AS A TOOL FOR MORE EFFICIENT AND ACCESSIBLE LABORATORY DIAGNOSTICS

Chromed role: MAIN INVESTIGATOR

Duration: 1st February 2023 - 31st December 2023

IV 8128 

DETERMINATION OF INDIVIDUAL FORMS OF VITAMIN K USING COMBINATION OF MODERN SEPARATION TECHNIQUES UHPLC-MS/MS AND ULTRACENTRIFUGATION APPLIED FOR FUTURE TESTING OF DIFFERENCES IN BLOOD COAGULATION PARAMETERS BETWEEN PATIENTS WITH METABOLIC DISORDERS AND HEALTHY CONTROLS

Chromed role: MAIN INVESTIGATOR

Duration: 1st February 2021 - 31st December 2021 (extended to 31st Decermber 2022)

IV 8148 

PROGNOSTIC MARKERS IN MONITORING OF NON-INFECTIOUS COMPLICATIONS IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY (CVID)

Chromed role: TEAM MEMBER

Duration: 1st February 2021 - 31st December 2021 (extended to 31st Decermber 2022)

IV 8158 

MITOCHONDRIAL RESPIRATION AND KYNURENINE/TRYPTOPHAN RATIO IN PATIENTS WITH GLIOBLASTOMA

Chromed role: TEAM MEMBER

Duration: 1st February 2021 - 31st December 2021 (extended to 31st Decermber 2022)

PROJECTS SUPPORTED BY MINISTRY OF HEALTH OF THE CZECH REPUBLIC

NU21J-02-00021 (AZV 9028)

DIFFERENCES IN PARAMETERS OF PLATELETS AGGREGATION AND BLOOD COAGULATION BETWEEN HEALTHY INDIVIDUALS AND PATIENTS WITH METABOLIC DIESASES

Metabolic disorders, diabetes and dyslipidemia, are known risk factors for development of atherosclerosis and hence cardiovascular diseases. Less is known that these diseases affect also directly platelet aggregation and blood coagulation. In particular, lower responsiveness of diabetic persons to antiplatelet drugs and higher sensitivity of platelets from familial hypercholesterolemic patients are already known phenomena. In this study, we aim to analyze platelet aggregation and blood coagulation in blood samples from healthy controls and patients suffering from diabetes mellitus I. type, familial hypercholesterolemia and metabolic syndrome. Sensitivity of both systems and the effect of older and novel drugs (acetylsalicylic acid, ticagrelor, vorapaxar, heparin, dabigatran, argatroban, rivaroxaban and apixaban) will be tested. In addition, modern markers of platelet hyperaggregability (monocyte-platelet complexes) and platelet-coagulation interconnection (platelet extracellular vesicles) will be tested and their relationship to sensitivity and the drug effect will be analyzed. In addition to the parameters routinely monitored in connection with these diseases, markers of immune system activation, and hence of atherosclerosis, such as neopterin and kynurenine will be determined. Furthermore, the concentrations of vitamin K as an important cofactor in the synthesis of coagulation proteins will be measured. This junior project will enable a tight collaboration between young talented researchers from both Faculty of Pharmacy of the Charles University and University Hospital in Hradec Králové.

Chromed role: CO-INVESTIGATOR

Evaluation: 

Duration: 1st May 2021 - 31st December 2024

NU22-A-108  (AZV 9301)

DETERMINATION OF POTENTIAL PROGNOSTIC LABORATORY MARKERS IN PATIENTS WITH COVID-19

Analyze selected laboratory markers in blood and urine samples in prospective study in hospitalized patients with COVID-19 with the effort to find suitable prognostic parameters (or their combinations) for possible prediction of the severity of the acute disease and the possible development of long-term consequences of COVID-19. 2. Subsequently monitor hospitalized patients with COVID-19 by selected laboratory markers in the post-covid ambulance UHHK and correlate their levels with the clinical status with an effort to find effective biomarkers that will be able to predict the prognosis of the disease, and the onset of post-covid syndrome. 3. To analyze urine as possible biofluid for this purpose as easily available biological material collected non-invasively and thus reduce the patients burden (compared to blood collection). 5. Using whole genome sequencing of the virus, find out its variant and correlate it with the clinical status of the patient and with the above-mentioned laboratory markers.

Chromed role: MAIN INVESTIGATOR

Evaluation:  EXCELLENT

Duration: 1st April 2022 - 31st December 2023

NV18-03-00130                                                                                                                                                         

SPECIFIC FACTORS AFFECTING THE TOXICITY OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a method combining extensive cytoreductive surgery with intraperitoneal administration of chemotherapy heated to 42°C. However, the combination of these anticancer treatments does not only result in better therapeutic response, but also in increased rate of adverse events and toxicity. The most common complications are circulatory and respiratory insufficiency, infectious complications, hematological toxicity, mineral dysbalance and dyspeptic complaints. The aim of this project is to study the toxicity of this therapy with regard not only to clinical and laboratory parameters, but also to potential biomarkers of immune response (neopterin, kynurenin, and tryptophan) and drug sensitivity (membrane transporters, DNA repair and apoptosis) to tracing relationships between immune response markers and toxicity, particularly in the context of infectious complications. By clarifying these associations, individualized prophylaxis, improvement of patient quality of life and treatment outcomes may be obtained. 

Chromed role:  CO-INVESTIGATOR

Evaluation: EXCELLENT

Duration: 1st May 2018 - 31st December 2021

17-28882A                                                                                                                                                                   

GENETIC PLYMORPHISMS, MICRORNAS AND BIOINDICATORS OF ACTIVITY: INTERRELATIONS IN THE DIAGNOSTICS AND THERAPY OF SEVERE FAMILIAL HYPERCHOLESTEROLEMIA

Chromed role: TEAM MEMBER

Rating: EXCELLENT

Duration: 1st of April 2017 - 31st of December 2020

17-29241A

PROPROTEIN CONVERTASE SUBTILISIN/KEXIN9 (PCSK9) IN THE PATHOPHYSIOLOGY AND TREATMENT OF DRY AGE-REALTED MACULAR DEGENARTION

Chromed role: TEAM MEMBER 

Rating: SUCCESSFUL

Duration: 1st of April 2017 - 31st of December 2020

17-31754A                                                                                                                                             

THE RELATIONSHIP OF SOLUBLE ENDOGLIN TO HYPERCHOLESTEROLEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND THE IMPACT OF THERAPEUTIC INTERVENTION

Chromed role: TEAM MEMBER 

Rating: EXCELLENT

Duration: 1st of April 2017 - 31st of December 2020

PROJECTS GIVEN BY GRANT AGENCY OF CHARLES UNIVERSITY

360221 

MODERN PREANALYSIS AS A TOOL FOR SOLVING COMPLICATIONS IN VITAMIN K DETERMINATION

Chromed role: MAIN INVESTIGATOR

Duration: 1st January 2021 - 31st December 2022